Residual disease in AML, a target that can move in more than one direction

Cytometry Part B - Clinical Cytometry

Volumn 86, Issue 1, 2014, Pages 15-17

  Loken, Michael R ^a  

^a HEMATOLOGICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOBLAST; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL POPULATION; CELL REGENERATION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENOTYPE; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE; LEUKEMIA RELAPSE; LIMIT OF DETECTION; MINIMAL RESIDUAL DISEASE; MYELOID PROGENITOR CELL; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE;

HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL;

EID: 84890565714     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21140     Document Type: Article

References (4)

1. Zeijlemaker W, Gratama J, Schuurhuis G,. Tumor heterogeneity makes AML a "moving target" for detection of residual disease. Cytometry B Clin Cytom (in press) DOI: 10.1002/cyto.b.21134.
2. Terstappen LWMM, Loken MR,. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Path 1990; 2: 229-240.
3. Terstappen LWMM, Konemann S, Safford M, Loken MR, Zurlutter K, Buchner TH, Hiddemann W, Wormann B,. Flow cytometric characterization of Acute Myeloid Leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1991; 6: 70-80.
4. Loken, MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S,. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012; 120: 1581-1588.